| Literature DB >> 35354489 |
Hai-Bo Ding1, Lin-Hui Wang2, Ge Sun1,3, Guan-Yu Yu1, Xian-Hua Gao1, Kuo Zheng1, Hai-Feng Gong1, Jin-Ke Sui1, Xiao-Ming Zhu1, Wei Zhang4.
Abstract
BACKGROUND: To investigate the learning curve of conformal sphincter preservation operation (CSPO) in the treatment of ultralow rectal cancer and to further explore the influencing factors of operation time.Entities:
Keywords: Conformal sphincter preservation operation; Learning curve; Operation time; Ultralow rectal cancer
Mesh:
Year: 2022 PMID: 35354489 PMCID: PMC8966240 DOI: 10.1186/s12957-022-02541-1
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Univariate analysis of influencing factors of CSPO operation time
| A vs. B | B vs. C | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age (》 65 years) | 2.105 | 0.706~6.280 | 0.182 | 1.75 | 0.571~5.360 | 0.327 |
| Gender (male) | 0.727 | 0.280~1.887 | 0.513 | 1 | 0.375~2.664 | 1 |
| BMI (》 25 Kg/m2) | 1.203 | 0.431~3.356 | 0.724 | 1.203 | 0.431~3.356 | 0.724 |
| Previous abdominal surgical history (yes) | 0.357 | 0.098~1.300 | 0.118 | 2.653 | 0.294–23.922 | 0.385 |
| Distance of tumor from anal verge (cm) | ||||||
| 2 ≦ | 1 | 1 | ||||
| 2 < *< 4 | 0.197 | 0.049~0.790 | 0.022 | 0.064–1.425 | 0.13 | |
| ≧ 4 | 0.46 | 0.159~1.328 | 0.151 | 0.105–0.867 | 0.026 | |
| Maximum diameter of mass (cm) | ||||||
| 2 ≦ | 1 | 1 | ||||
| 2 < * < 4 | 1.591 | 0.395~6.407 | 0.514 | 1.909 | 0.563–6.477 | 0.3 |
| ≧ 4 | 0.625 | 0.181~2.155 | 0.457 | 1.455 | 0.454–4.655 | 0.528 |
| ASA classification | 2.57 | 0.812~8.132 | 0.108 | 1.123 | 0.353–3.567 | 0.845 |
| Neoadjuvant therapy (yes) | 4.6 | 1.4~15.117 | 0.012 | 1.6 | 0.610–4.139 | 0.339 |
| CE (》 5 ng/ml) | 1.395 | 0.440~4.424 | 0.572 | 1.395 | 0.440–4.424 | 0.572 |
| CA19-9 (》 37 U/ml) | 0.308 | 0.048~1.964 | 0.213 | 0.481 | 0.064–3.614 | 0.477 |
| T stage | ||||||
| T0 | 1 | 1 | ||||
| T1 | 1.436 | 0.00~2.176 | 0.999 | 1.974 | 0–2.324 | 0.999 |
| T2 | 1 | 0.260~3.845 | 1 | 2.2 | 0.54–8.957 | 0.27 |
| T3 | 2.424 | 0.747~7.862 | 0.14 | 3.333 | 1.088–10.211 | 0.035 |
| N stage | ||||||
| N0 | 1 | 1 | ||||
| N1 | 1.119 | 0.096~13.032 | 0.928 | 0 | 0–2.221 | 0.999 |
| N2 | 0.615 | 0.034~7.452 | 0.615 | 0 | 0–2.324 | 0.999 |
| TNM comprehensive staging | ||||||
| 0 | 1 | 1 | ||||
| I | 1.615 | 0~2.157 | 0.999 | 1.615 | 0–2.221 | 0.999 |
| II | 2.059 | 0.577~7.341 | 0.266 | 2.5 | 0.688–9.084 | 0.164 |
| III | 1.75 | 0.329~9.298 | 0.511 | 1 | 0.214–4.674 | 1 |
Multivariate analysis of influencing factors of CSPO operation time
| A vs B | B vs C | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Distance of tumor from anal verge (cm) | ||||||
| 2 ≦ | 1 | 1 | ||||
| 2 < * < 4 | 2.388 | 0.548–10.404 | 0.246 | 1.15 | 0.207–6.387 | 0.873 |
| ≧ 4 | 5.18 | 1.086–24.701 | 0.039 | 4.677 | 0.785–27.867 | 0.09 |
| Neoadjuvant therapy (yes) | 2.973 | 0.793–11.143 | 0.106 | 0.902 | 0.282–2.888 | 0.863 |
| T stage | ||||||
| T0 | 1 | 1 | ||||
| T1 | 1.097 | 0–1.253 | 0.999 | 2.63 | 0–2.324 | 0.999 |
| T2 | 0.81 | 0.175–3.759 | 0.788 | 1.599 | 0.317–8.068 | 0.57 |
| T3 | 2.018 | 0.557–7.316 | 0.285 | 4.378 | 1.239–15.470 | 0.022 |
Baseline characteristics
| Total ( | Learning period (45 cases) | Completion period (63 cases) | |||
|---|---|---|---|---|---|
| Gender (cases) | 0.247 | ||||
| Male | 70 (64.8%) | 32 (29.6%) | 38 (35.2%) | ||
| Female | 38 (35.2%) | 13 (12%) | 25 (23.2%) | ||
| Age (years) | 57.0 ± 10.9 | 56.3 ± 12.0 | 57.5 ± 10.0 | 0.578 | |
| BMI (Kg/m2) | 23.0 ± 3.3 | 23.2 ± 3.7 | 22.9 ± 3.0 | 0.633 | |
| ASA classification | 0.278 | ||||
| 1 | 9 (8.3%) | 5 (4.6%) | 4 (3.7%) | ||
| 2 | 92 (85.2%) | 38 (35.2%) | 54 (50%) | ||
| 3 | 7 (6.5%) | 2 (1.9%) | 5 (4.6%) | ||
| 4 | 0 | 0 | 0 | ||
| Previous abdominal surgical history | 0.535 | ||||
| Yes | 12 (11.1%) | 4 (3.7%) | 8 (7.4%) | ||
| No | 96 (88.9%) | 41 (38%) | 55 (50.9%) | ||
| Neoadjuvant therapy | 0.16 | ||||
| Yes | 37 (34.3%) | 12 (11.1%) | 25 (23.2%) | ||
| No | 71 (65.7%) | 33 (30.5%) | 38 (35.2%) | ||
| CEA (ng/ml) | 0.781 | ||||
| Abnormal | 23 (21.3%) | 9 (8.3%) | 14 (13%) | ||
| Normal | 85 (78.7%) | 36 (33.3%) | 49 (45.4%) | ||
| CA19-9 (U/ml) | 0.947 | ||||
| Abnormal | 7 (6.5%) | 3 (2.8%) | 4 (3.7%) | ||
| Normal | 101 (93.5%) | 42 (38.9%) | 59 (54.6%) | ||
| Intraoperative blood loss (ml) | 168.8 ± 87.2 | 204.7 ± 99.7 | 143.1 ± 67.1 | 0 | |
| Number of harvested lymph nodes | 12.8 ± 4.6 | 13.3 ± 4.5 | 12.4 ± 4.7 | 0.323 | |
| Distance of tumor from anal verge (cm) | 3.4 ± 1.1 | 3.2 ± 0.9 | 3.5 ± 0.9 | 0.192 | |
| Distal resection margin (cm) | 0.7 ± 0.5 | 0.6 ± 0.4 | 0.7 ± 0.6 | 0.393 | |
| Maximum diameter of mass (cm) | 3.0 ± 1.4 | 3.1 ± 1.7 | 2.9 ± 1.2 | 0.342 | |
| Preoperative tumor gross type | 0.683 | ||||
| No/scar | 10 (9.3%) | 5 (4.6%) | 5 (4.7%) | ||
| Ulcerative | 61 (56.5%) | 23 (21.3%) | 38 (35.2%) | ||
| Proliferated | 36 (33.3%) | 16 (14.8%) | 20 (18.5%) | ||
| Infiltrated | 1 (0.9%) | 1 (0.9%) | 0 | ||
| The degree of tumor differentiation | 0.672 | ||||
| No/premalignant lesion | 12 (11.1%) | 5 (4.6%) | 7 (6.5%) | ||
| High differentiation | 6 (5.6%) | 1 (0.9%) | 5 (4.7%) | ||
| Medium differentiation | 83 (76.8%) | 36 (33.3%) | 47 (43.5%) | ||
| Low differentiation | 7 (6.5%) | 3 (2.8%) | 4 (3.7%) | ||
| cT stage | 0.132 | ||||
| 0 | 0 | 0 | 0 | ||
| 1 | 18 (16.7%) | 8 (7.4%) | 10(9.3%) | ||
| 2 | 51 (47.2%) | 24 (22.2%) | 27 (25%) | ||
| 3 | 38 (35.2%) | 13 (12%) | 25 (23.2%) | ||
| 4 | 1 (0.9%) | 0 | 1 (0.9%) | ||
| cN stage | 0.883 | ||||
| 0 | 63 (58.3%) | 28 (25.9%) | 35 (32.4%) | ||
| 1 | 33 (30.6%) | 12 (11.1%) | 21 (19.5%) | ||
| 2 | 12 (11.1%) | 5 (4.6%) | 7 (6.5%) | ||
| pT stage | 0.559 | ||||
| 0 | 6 (5.6%) | 3 (2.8%) | 3 (2.8%) | ||
| 1 | 22 (20.4%) | 9 (8.3%) | 13 (12.1%) | ||
| 2 | 52 (48.1%) | 23 (21.3%) | 29 (26.8%) | ||
| 3 | 28 (25.9%) | 10 (9.3%) | 18 (16.6%) | ||
| 4 | 0 | 0 | 0 | ||
| pN stage | 0.448 | ||||
| 0 | 89 (82.4%) | 35 (32.4%) | 54 (50%) | ||
| 1 | 16 (14.8%) | 9 (8.3%) | 7 (6.5%) | ||
| 2 | 3 (2.8%) | 1 (0.9%) | 2 (1.9%) | ||
| pTNM comprehensive staging | 0.642 | ||||
| 0 | 6 (5.6%) | 3 (2.8%) | 3 (2.8%) | ||
| I | 66 (61.2%) | 27 (25%) | 39 (36.2%) | ||
| II | 18 (16.6%) | 5 (4.6%) | 13 (12%) | ||
| III | 18 (16.6%) | 10 (9.3%) | 8 (7.3%) | ||
| IV | 0 | 0 | 0 | ||
| Postoperative complications | 0.432 | ||||
| Yes | 18 (16.7%) | 9 (8.3%) | 9 (8.4%) | ||
| No | 90 (83.3%) | 36 (33.3%) | 54 (50%) | ||
| Postoperative infection | 0.217 | ||||
| Yes | 10 (9.3%) | 6 (5.6%) | 4 (3.7%) | ||
| No | 98 (90.7%) | 39 (36.1%) | 59 (54.6%) | ||
| Classification of complications | 0.825 | ||||
| 0 | 90 (83.3%) | 36 (33.3%) | 54 (50%) | ||
| I | 3 (2.8%) | 3 (2.8%) | 0 | ||
| II | 14 (13%) | 6 (5.6%) | 8 (7.3%) | ||
| III | 1 (0.9%) | 0 | 1 (0.9%) | ||
| IV | 0 | 0 | 0 | ||
| V | 0 | 0 | 0 | ||
| Flatus and defecation time (days) | 2.1 ± 0.6 | 2.3 ± 0.4 | 2.1 ± 0.6 | 0 | |
| Postoperative liquid diet time (days) | 2.6 ± 0.6 | 2.7 ± 0.5 | 2.5 ± 0.7 | 0 | |
| Postoperative hospital stay (days) | 6.2 ± 2.6 | 6.9 ± 2.9 | 5.6 ± 2.2 | 0.002 | |
| Closure of stoma | 0.201 | ||||
| Yes | 102 (94.4%) | 44 (40.7%) | 58 (53.7%) | ||
| No | 6 (5.6%) | 1 (0.9%) | 5 (4.7%) | ||
| Duration of stoma (median months) | 8 | 7 | 9 | 0.044 | |
| PFS3 | 95/108; 88.0% | 38/45; 84.4% | 57/63; 90.5% | 0.342 | |
| OS3 | 101/108; 93.5% | 40/45; 88.9% | 61/63; 96.8% | 0 | |
Values are reported as mean ± SD or as median and interquartile range
CEA > 5 ng/ml and CA19-9 > 37 U/ml were judged as abnormal
Fig. 1Moving average curve of CSPO operation time. →The first lowest point of the moving average curve
Fig. 2CUSUM curve of CSPO operation time. │Vertical line through CUSUM curve cutoff point
Fig. 3Learning curve flow chart